中国普通外科杂志 ›› 2021, Vol. 30 ›› Issue (3): 269-275.doi: 10.7659/j.issn.1005-6947.2021.03.004

• 专题研究 • 上一篇    下一篇

NIMA相关激酶2在胰腺癌中的表达及其临床意义

刘向梅,许达峰,王春玲,符于正,王丹,武金才   

  1. (海南省人民医院/海南医学院附属海南医院  肝胆胰外科,海南 海口  570000)
  • 收稿日期:2021-01-10 修回日期:2021-02-28 出版日期:2021-03-25 发布日期:2021-04-06
  • 通讯作者: 武金才, Email: jincaiwu73@sina.com
  • 作者简介:刘向梅,海南省人民医院/海南医学院附属海南医院主管护师,主要从事肝胆胰常见疾病及肿瘤基础方面的研究。
  • 基金资助:
    海南省自然科学基金资助项目(819QN356;820MS130)。

Expression of NIMA-related kinase 2 in pancreatic cancer and its clinical significance

LIU Xiangmei, XU Dafeng, WANG Chunling, FU Yuzheng, WANG Dan, WU Jincai   

  1. (Department of Hepatobiliary and Pancreatic Surgery, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University,  Haikou, 570000, China)
  • Received:2021-01-10 Revised:2021-02-28 Online:2021-03-25 Published:2021-04-06

摘要: 背景与目的:NIMA相关激酶2(NEK2)在多种恶性肿瘤中呈高表达,且与肿瘤进展及不良预后密切相关。然而,NEK2在胰腺癌中的表达及意义尚不清楚。因此,本研究探讨NEK2在胰腺癌组织中的表达及其与患者临床病理因素、预后的关系。
方法:收集海南省人民医院肝胆胰外科于2013年1月—2014年12月接受胰腺癌切除术的108例患者组织标本,以及临床病理资料与随访资料。免疫组化法染色检测组织标本中NEK2的表达,分析NEK2的表达与临床病理因素的关系,Kaplan-Meier生存曲线和Log-rank分析及比较不同NEK2表达水平患者无瘤生存率及总生存率差异。Cox风险比例模型分析影响预后的危险因素。
结果:在正常胰腺组织中无NEK2表达,108例胰腺癌组织中,NEK2高表达63例(58.3%),低表达45例(41.7%)。NEK2的表达与患者CA19-9水平(P=0.015)﹑TNM分期(P=0.002)﹑肿瘤分化程度(P=0.034)﹑淋巴结转移(P=0.043)明显有关,而与性别﹑年龄﹑吸烟﹑CEA水平﹑肿瘤大小﹑肿瘤部位无明显关系(均P>0.05)。NEK2高表达患者1﹑3、5年无瘤生存率分别为60.5%﹑20.7%、5.2%,NEK2低表达患者1﹑3、5年无瘤生存率分别为75.4%﹑50.6%、24.9%;NEK2高表达患者1﹑3、5年总生存率分别为75.6%﹑42.2%、15.3%,NEK2低表达患者1﹑3、5年总生存率分别为85.7%﹑60.6%、30.1%,NEK2高表达患者的无瘤生存率与总生存率均低于NEK2低表达患者(均P<0.05)。单因素与多因素分析结果显示,TNM分期(P=0.029)﹑淋巴结转移(P=0.016)、NEK2高表达(P=0.032)为无瘤生存率的独立影响因素;TNM分期(P=0.035)﹑分化程度(P=0.042)﹑淋巴结转移(P=0.006)及NEK2高表达(P=0.000)为总生存率的独立影响因素。
结论:NEK2高表达是胰腺癌患者预后的独立危险因素,NEK2可作为胰腺癌术后患者预后判断的指标。

关键词: 胰腺肿瘤, NIMA相关激酶2, 预后

Abstract: Background and Aims: The expression of NIMA-related kinase 2 (NEK2) is increased in a variety of malignant tumors, and is closely associated with tumor progression and patients’ unfavorable prognosis. However, the expression of NEK2 and its significance in pancreatic cancer are still unclear. Therefore, this study was conducted to investigate the NEK2 expression in pancreatic cancer tissue and its relationship with clinicopathologic factors and prognosis of the patients.  
Methods: The surgical specimens from 108 patients with pancreatic cancer undergoing pancreatectomy from January 2013 to December 2014 in the Department of Hepatopancreatobiliary Surgery of Hainan Provincial People's Hospital as well as the clinicopathologic and follow-up data of these patients were collected. The expressions of NEK2 in the tissue samples were detected by immunohistochemical staining. The relations of NEK2 with the clinicopathologic factors were analyzed, and the difference in tumor-free survival and overall survival rates between patients with different NEK2 expression levels were analyzed and compared by Kaplan-Meier survival curve and Log-rank analysis. The prognostic factors were determined by Cox proportional hazard model.
Results: There was no NEK2 expression in the normal pancreatic tissue, while in the 108 samples of pancreatic cancer tissue, high and low NEK2 expressions were found in 63 cases (58.3%) and 45 cases (41.7%), respectively. The NEK2 expression was significantly associated with CA19-9 level (P=0.015), TNM stage (P=0.002), tumor differentiation (P=0.034), and lymph node metastasis (P=0.043), but irrelevant to sex, age, smoking, CEA level, tumor size and tumor location (all P>0.05). The 1-, 3- and 5-year disease-free survival rates were 60.5%, 20.7% and 5.2% in patients with high NEK2 expression, and 75.4%, 50.6% and 24.9% in patients with low NEK2 expression, and the 1-, 3- and 5-year overall survival rates were 75.6%, 42.2% and 15.3% in patients with NEK2 expression, and 85.7%, 60.6% and 30.1% in patients with low NEK2 expression, respectively. Both disease-free survival and overall survival rates in patients with high NEK2 expression were significantly lower than those in patients with low NEK2 expression (both P<0.05). Univariate and multivariate analysis showed that TNM stage (P=0.029), lymph node metastasis (P=0.016) and NEK2 high expression (P=0.032) were independent influencing factors for tumor-free survival, and TNM stage (P=0.035), degree of differentiation (P=0.042), lymph node metastasis (P=0.006) and NEK2 high expression (P=0.000) were independent influencing factors for overall survival. 
Conclusion: High NEK2 expression is an independent risk factor for the prognosis of pancreatic carcinoma patients, and NEK2 can be used as an indicator for prognosis of pancreatic carcinoma patients after operation.

Key words: Pancreatic Neoplasms, NIMA-Related Kinase2, Prognosis

中图分类号: 

  • R735.9 
[1] 韩仕锋, 金春风, 朱磊. 预后指数在可切除胰腺导管腺癌患者术后评估中临床价值[J]. 中国普通外科杂志, 2021, 30(3): 247-253.
[2] 秦雯, 陈泰文, 郑海平, 杨建宇, 朱小东. 血清ANGPTL2与胰腺癌临床病理特征的关系及其在胰腺癌诊断中的价值[J]. 中国普通外科杂志, 2021, 30(3): 254-260.
[3] 李铭旭, 仲成成, 张功铭, 胡伟, , 王仲, . DEP结构域蛋白质1B在胰腺癌中的表达及其临床意义[J]. 中国普通外科杂志, 2021, 30(3): 261-268.
[4] 张波, 徐涛, 徐浩, 夏雨, 周文策, . 基于生物信息学胰腺腺癌关键基因的筛选及支持向量机诊断模型的构建[J]. 中国普通外科杂志, 2021, 30(3): 276-285..
[5] 李威威, 刘金龙. 循环肿瘤DNA在胰腺癌中的临床应用进展[J]. 中国普通外科杂志, 2021, 30(3): 337-342.
[6] 谢学文, 费书珂. 中性粒细胞胞外诱捕网与胰腺疾病的研究进展[J]. 中国普通外科杂志, 2021, 30(3): 343-348.
[7] 王蒲雄志, 于新哲, 史向军, 袁周 . 胰腺导管腺癌的免疫治疗研究进展 [J]. 中国普通外科杂志, 2021, 30(3): 330-336.
[8] 刘继升, 刘河, 刘浩, YU Xing, 李浩. TIP30在肝内胆管癌中的表达及意义[J]. 中国普通外科杂志, 2021, 30(2): 187-194.
[9] 张帆, 李泽东, 彭禹, 陈胜, 周钧. 基于血清miRNA表达数据的胰腺癌诊断决策树构建[J]. 中国普通外科杂志, 2021, 30(2): 211-218.
[10] 李留峥, 王峻峰, 徐雷升, 敖强, 高学昌, 龚国茶, 谌蔚雯, 王雪, 俸家伟. 肝门部胆管癌手术治疗:附44例报告[J]. 中国普通外科杂志, 2021, 30(2): 140-150.
[11] 李俊, 李理, 李勇敢, 赵延兵, 张玮, 苏瑜恒, 张洁, 李世朋. 血清lncRNA HULC水平与乙型肝炎病毒相关性肝细胞癌患者临床特征及预后的关系[J]. 中国普通外科杂志, 2021, 30(1): 64-70.
[12] 魏永健, 任龙飞, 张磊, 李汛. 术前血小板与淋巴细胞比值对肝癌切除术后患者预后价值的Meta分析[J]. 中国普通外科杂志, 2021, 30(1): 44-54.
[13] 周发权, 陈师, 孙红玉, 汤礼军. 系统免疫炎症指数与胰腺癌患者预后关系的系统评价和Meta分析[J]. 中国普通外科杂志, 2020, 29(9): 1076-1083.
[14] 曹利军, 张频捷, 胡秋源, 陈虎, 孙昀. 气肿性胰腺炎3例报告并文献复习[J]. 中国普通外科杂志, 2020, 29(9): 1098-1104.
[15] 龙官保, 黎昕, 肖朝文, 张俊, 赵新阳, 蔡常春. 紧邻主胰管的胰腺囊性肿瘤局部切除的初步经验:附4例报告[J]. 中国普通外科杂志, 2020, 29(9): 1147-1150.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 龚丽, 欧阳文, 裴琛琳, 陈志康, 朱红, 董超, . 妊娠合并BRAF突变晚期结肠癌国际会诊病例诊治体会并文献复习[J]. 中国普通外科杂志, 2020, 29(4): 510 -514 .
[2] 赵文娟, 朱燕梅, 李晓玲, 秦洁 . 基于微信平台的围手术期干预在乳腺癌全程个案管理中的应用[J]. 中国普通外科杂志, 2020, 29(5): 630 -634 .
[3] 肖卫星,周君,顾梦佳,肖广远. 精准肝切除在肝内胆管结石手术治疗中的应用[J]. 中国普通外科杂志, 2016, 25(2): 191 -196 .
[4] 杨艳婷, 鲁明典, 夏俊, 郑慧, 童清平, 毛萍 . 腔内超声与高分辨薄层直肠MRI新序列在术前评估与直肠癌术后病理结果的对比分析[J]. 中国普通外科杂志, 2020, 29(4): 498 -503 .
[5] 白宁1, 2|王栋2|欧阳锡武2|周乐杜2|王志明2. 苦参碱对大鼠肝缺血再灌注损伤的抑制作用及机制[J]. , 2018, 27(1): 81 -86 .
[6] 肖润沙, 唐文彬, 陈子华, 成小苗. 胃肠道肿瘤合并肾损害30例报告并文献复习[J]. 中国普通外科杂志, 2020, 29(4): 504 -509 .
[7] 黄隽, 胡元萍, 陈创, 齐晓伟. 新型冠状病毒肺炎疫情特殊时期对乳腺癌治疗临床问题的若干思考[J]. 中国普通外科杂志, 2020, 29(2): 153 -160 .
[8] 廖信芳1,李正荣2,杨清水1,张乡城2, 李柱1,揭志刚2. microRNA-139-5p及其靶基因Notch1在结直肠癌中的作用[J]. 中国普通外科杂志, 0, (): 1373 -1378 .
[9] 项灿宏|童翾 . 肝门部胆管癌外科治疗的进展与争议[J]. , 2018, 27(2): 137 -142 .
[10] 黄耿文|申鼎成|何文|杨柳|周书毅|阳建怡|纪连栋|魏伟. 快速康复模式下的腹腔镜腹股沟疝修补术[J]. , 2016, 25(10): 1470 -1474 .